CEM designed, developed, and introduced the world's first microwave peptide synthesizer to the scientific community in 2003. Since that time, CEM has expanded its portfolio to include manual, semi-automated, fully automated (single channel), and fully automated (12-channel) systems. All of CEM's peptide synthesizers can operate under conventional conditions, microwave conditions, or a combination of both. Both fully automated systems can be equipped with an optional UV monitoring system. Additionally, the manual and semi-automated systems can be upgraded to either of the fully automated versions.
Each one of CEM's peptide synthesizers utilizes in-situ fiber optic temperature monitoring during heating. In-situ temperature monitoring helps avoid temperature overshoots from use of external IR monitoring, which can lead to significant side reactions. In 2007, researchers at CEM showed in a major publication that precise temperature control limits major side reactions such as racemization and aspartimide formation(2). CEM's methods are now routinely used in hundreds of laboratories worldwide.
(1) Including among others US7,563,865; US7,582,728; US7,393,920, EP1491552. Additional International Patents filed and pending.
(2) Palasek S., Cox Z., Collins J., J. Pept. Sci.13,143-148, 2007.
CEM Corporation, a private company based in Matthews, North Carolina, is the leading global company specializing in scientific solutions for critical laboratory applications. The Company has subsidiaries in the United Kingdom,
|SOURCE CEM Corporation|
Copyright©2010 PR Newswire.
All rights reserved